Thank you to the Greater Houston Partnership for inviting Tvardi Leadership to speak today at the inaugural Bayou City Bio Pulse and engage with members of the Greater Houston Life Sciences Community. We look forward to next Bayou City Bio Pulse event. #LifeSciences

As an official sponsor for the Pulmonary Fibrosis Foundation Dallas PFF Walk 2023 we are looking forward to seeing everyone tomorrow (October 21st) in DFW! Our Phase 2 REVERT IPF trial is open and recruiting #IPF patients throughout the US (clinicaltrials.gov/study/NCT05671…). Register: pulmonaryfibrosis.org/get-involved/e…

Thank you BioHouston & @RiceAlliance for honoring Tvardi as the 2023 private company spotlight speaker at #TexasLifeScienceForum. Exciting to present as we were selected as a Most Promising Life Science Company in 2020. Great forum to highlight our P2 studies in #IPF #HCC #mBC

The Tvardi management team will present PiperSandler 35thAnnual Healthcare Conference and participate in one-on-one meetings with investors on November 28, 2023, in NYC. #hepatocellularcarcinoma #HCC #breastcancer #IdiopathicPulmonaryFibrosis tvarditherapeutics.com/2023/11/21/tva…

We are excited to share that Tvardi leadership will present a trial-in-progress poster at the upcoming 2024 GI ASCO for the ongoing REVERT LIVER CANCER trial #HCC #GI24 tvarditherapeutics.com/2024/01/18/tva…

Tvardi leadership was met with great enthusiasm as they presented the trial-in-progress poster today for the ongoing REVERT LIVER CANCER trial at 2024 GI ASCO.

Tvardi management will hold one-on-one investor meetings at the TDCowenResearch 44th Annual Health Care Conference on March 4, 2024, in Boston, MA #hepatocellularcarcinoma #HCC #idiopathicpulmonaryfibrosis tvarditherapeutics.com/2024/03/01/tva…

We are pleased to announce the appointment of Sujal Shah as Chairman and the addition of Shaheen Wirk to the Tvardi Board of Directors. tvarditherapeutics.com/2024/03/25/tva…

Tvardi Therapeutics will participate in a #firesidechat at 10:00 AM ET on August 6th and will hold investor meetings on August 5-6 at the 2024 BTIG Virtual Biotechnology Conference. #HepatocellularCarcinoma #IdiopathicPulmonaryFibrosis #ClinicalTrial tvarditherapeutics.com/2024/07/31/tva…

We are pleased to announce that Imran Alibhai, PhD, CEO of Tvardi Therapeutics, was selected to make a presentation and co-lead a panel discussion at the 8th Annual IPF Summit being held in Boston, MA on August 22, 2024.#IdiopathicPulmonaryFibrosis tvarditherapeutics.com/2024/08/14/tva…

Tvardi is a proud sponsor for the Pulmonary Fibrosis Foundation PFF Walk taking place Saturday (9/14) in Chicago. Join our leadership team and members of the PFF community as we walk together toward a cure! If you have not registered for the PFF Walk, please register here: pulmonaryfibrosis.org/get-involved/e…

We are pleased to present preclinical data on TTI-101 that supports our Phase 2 REVERT IPF Clinical Trial at the CHEST 2024 Annual Meeting on October 8th, 2024, in Boston, MA. #IdiopathicPulmonaryFibrosis tvarditherapeutics.com/2024/10/02/tva…

Today, we announce a proposed reverse merger with Cara to continue developing novel treatments for fibrosis-driven diseases. We look forward to leveraging our combined resources to advance our STAT3 inhibitor platform through Phase 2 studies in IPF and HCC tvarditherapeutics.com/2024/12/18/car…

Tvardi management will host one-on-one investor meetings at the TD Cowen 45th Annual Health Care Conference on March 3 – 5, 2025, in Boston, MA. Join us for insights into our Phase 2 STAT3 programs in fibrosis-driven diseases. bit.ly/3ETEOJg

Tvardi Therapeutics Announces Publication of Results from First-in-Human Study of TTI-101 in Patients with Advanced Solid Tumors in the Journal Clinical Cancer Research tvarditherapeutics.com/2025/03/19/tva…

Merger creates a Nasdaq-listed, clinical-stage biopharmaceutical company – Tvardi Therapeutics – developing novel treatments targeting STAT3 to treat fibrosis-driven diseases. Tvardi shares to begin trading under the symbol “TVRD” on April 16, 2025 bit.ly/3GdyvRy

bit.ly/3GdyvRy

Tvardi Therapeutics Announces Presentation at the American Thoracic Society 2025 Annual Conference bit.ly/4jY9rME

Tvardi’s Management will participate in the Piper Sandler 3rd Annual Virtual Lung Symposium with ATS Takeaways: Tuesday, May 27, 2025, and the Jefferies Global Healthcare Conference: June 3 – 5, 2025, in New York, NY bit.ly/3ZoJY7i

The REVERT IPF Phase 2 clinical trial is a randomized, double-blind, placebo-controlled clinical trial of TTI-101 in patients suffering from IPF. Key endpoints include safety and lung function (FVC). Topline data is anticipated in 4Q 2025. bit.ly/3SkgbJd